Efforts to target downstream kinases have focused on RAF, MEK, and ERK, almost exclusively in neoplasms with wild-type RAS. Clinical trials evaluating the efficacy of MEK1/2 inhibitors in AML have shown promising albeit mixed results [10,11,12]. Here, RAF1 is linked to acute myeloid leukemia.